Thymus Lymphoma

hematologic malignancy

Identifier: CI-CAN-00004112
Entity page: /cancer/thymus-lymphoma ↗
Edges: 176

Neighbours: 15 drugs10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Thymus Lymphoma approved for …APPROVED_FORderived1 of 1
← approved for	Pembrolizumabmonoclonal antibody FDA (US) · approved · 2014-09-04 · Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have rela…	—	approved	Primary Mediastinal Large B-Cell Lymphoma	1	Regulatory	openfda	graph →
Thymus Lymphoma …

Thymus Lymphoma studied in …STUDIED_INderived10 of 127show all (up to 200)
→ studied in	NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06784167recruiting Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05359211Phase 1 · completed NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07168486Phase 1 · enrolling by invitation CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05934084NA · recruiting Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06830031Phase 1 · recruiting Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma · condition mapped ALIAS · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07098364Phase 1/Phase 2 · suspended ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04759586Phase 3 · active not recruiting Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03625037Phase 1/Phase 2 · active not recruiting First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains